Lactose (India) Ltd

For the second consecutive session, Lactose (India) Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 83.5 on 20 Mar 2026. This drop comes amid a broader market that is showing modest gains, highlighting a stark divergence for this pharmaceuticals micro-cap.

Lactose (India) Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Lactose (India) Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lactose (India) Limited, a Gujarat-based pharmaceutical ingredients manufacturer, reported a sharp deterioration in profitability for Q3 FY26, with net profit collapsing 75.46% quarter-on-quarter to ₹0.53 crores from ₹2.16 crores in Q2 FY26. The ₹133-crore market capitalisation company's results revealed concerning margin compression despite modest revenue growth, triggering a bearish technical reversal that has pushed the stock down 32.55% over the past year.

Lactose (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 Feb 2026, driven primarily by improvements in its technical indicators despite ongoing fundamental challenges. The company’s Mojo Score now stands at 34.0, reflecting a cautious but slightly more optimistic stance amid mixed signals from valuation, financial trends, and quality metrics.

Lactose (India) Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 February 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results, the company’s stock continues to underperform the broader market, weighed down by bearish technical trends, weak long-term fundamentals, and valuation concerns.

Lactose (India) Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average, signalling a potential shift towards a bearish trend. This development reflects a deterioration in the stock’s momentum and raises concerns about its medium to long-term outlook amid already challenging market conditions.

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Lactose (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Lactose (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical indicators and financial performance metrics. While the stock has shown signs of technical recovery, its financial fundamentals present a complex picture, prompting a reassessment of its investment profile.

Lactose (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment following a detailed analysis of its quality, valuation, financial trends, and technical indicators. Despite some positive quarterly financial results, the stock’s recent performance and underlying fundamentals have prompted a reassessment of its investment profile.

Lactose (India), a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a revision in its market evaluation metrics. This shift reflects a nuanced reassessment of the company’s financial and technical parameters, set against a backdrop of fluctuating stock returns and sector dynamics.

Lactose (India) Ltd is experiencing notable buying activity, with a significant stock increase today and a strong performance over the past week. The stock has shown resilience despite earlier challenges, reflecting a positive trend in the pharmaceuticals and biotechnology sector, supported by robust buyer sentiment.